Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...

The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials ...

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter ...

A hot (if cautious) topic at the big gene therapy meeting: what Vinay Prasad's appointment might mean for approvals in rare ...

If there’s anything that Dr. Vinay Prasad, the controversial new appointee to lead the Center for Biologics Evaluation and Research, or CBER, a top office at the Food and Drug Administration ...

The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...

At the American Society of Cell and Gene Therapy conference, there were questions and qualms on how Vinay Prasad may change ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene therapies, and blood supply.

From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...

Prasad's appointment marks the latest addition of a medical skeptic and critics of COVID-19 policies to federal health leadership.

The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA leadership and ...